Anxiety is the most common mental health condition in the UK, affecting an estimated 8 million people at any given time. For many, conventional treatments — SSRIs, CBT, lifestyle changes — work well enough. For a significant minority, they don't work at all.
In the gap between those two groups, medical cannabis has found a growing patient base. But the relationship between cannabinoids and anxiety is complicated, and the evidence deserves careful reading.
What Works: The CBD Evidence
The strongest data supports cannabidiol, or CBD. A 2019 randomised controlled trial published in the Journal of Psychopharmacology found that a single 300mg dose of CBD significantly reduced anxiety during a simulated public speaking test — the gold-standard model for studying social anxiety. Participants who received CBD showed lower heart rates, lower blood pressure, and reduced subjective anxiety compared to placebo.
A 2022 systematic review in the British Journal of Pharmacology examined 28 studies on CBD and anxiety. The conclusion was cautiously positive: CBD demonstrated anxiolytic effects across multiple study designs and anxiety subtypes, with a favourable safety profile. The authors noted that most studies were small and short-term, but the consistency of the signal warranted larger trials.
For patients with generalised anxiety disorder, the evidence base is thinner but growing. Observational data from UK cannabis clinics, including the Project Twenty21 registry, suggests that patients prescribed CBD-dominant products report meaningful reductions in anxiety scores over three to six months of treatment.
The THC Question
THC's relationship with anxiety is more complicated — and dose-dependent. At low doses, some patients report that THC reduces anxiety and improves sleep. At higher doses, the same compound can induce or worsen anxiety, particularly in inexperienced users. This biphasic effect is well-documented: the same molecule produces opposite effects depending on the dose and the individual's neurochemistry.
For this reason, most UK clinicians prescribing for anxiety start with CBD-dominant formulations and introduce THC cautiously, if at all. The goal is anxiolysis without intoxication — a therapeutic window that exists but requires careful titration.
Who Should Be Cautious
The evidence also identifies populations for whom cannabis-based treatment may carry elevated risk. People with a personal or family history of psychosis should approach THC-containing products with particular caution. A 2019 meta-analysis in The Lancet Psychiatry found that daily cannabis use, particularly of high-potency products, was associated with increased risk of psychotic disorders in vulnerable individuals.
This does not mean cannabis causes psychosis — the absolute risk remains low — but it does mean clinicians and patients need to screen carefully and proceed with appropriate caution.
The Bottom Line
The evidence for CBD as an anxiolytic is promising and growing. The evidence for THC is mixed and highly individual. For patients who have exhausted conventional options — who have tried the medications, completed the therapy, and are still struggling — prescribed medical cannabis may represent a legitimate next step. But it should be approached with the same clinical rigour applied to any other psychiatric intervention: careful assessment, conservative dosing, and systematic follow-up.
Anxiety is not a single condition with a single mechanism. Neither is cannabis. Matching the right patient to the right formulation, at the right dose, is where clinical judgement — and more research — matters most.
